Literature DB >> 28533779

Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections.

David F G Malone1, Sebastian Lunemann2, Julia Hengst1,3, Hans-Gustaf Ljunggren1, Michael P Manns3,4, Johan K Sandberg1, Markus Cornberg3,4, Heiner Wedemeyer3,4, Niklas K Björkström1.   

Abstract

Adaptive-like expansions of natural killer (NK) cell subsets are known to occur in response to human cytomegalovirus (CMV) infection. These expansions are typically made up of NKG2C+ NK cells with particular killer-cell immunoglobulin-like receptor (KIR) expression patterns. Such NK cell expansion patterns are also seen in patients with viral hepatitis infection. Yet, it is not known if the viral hepatitis infection promotes the appearance of such expansions or if effects are solely attributed to underlying CMV infection. In sizeable cohorts of CMV seropositive hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis delta virus (HDV) infected patients, we analyzed NK cells for expression of NKG2A, NKG2C, CD57, and inhibitory KIRs to assess the appearance of NK cell expansions characteristic of what has been seen in CMV seropositive healthy individuals. Adaptive-like NK cell expansions observed in viral hepatitis patients were strongly associated with CMV seropositivity. The number of subjects with these expansions did not differ between CMV seropositive viral hepatitis patients and corresponding healthy controls. Hence, we conclude that adaptive-like NK cell expansions observed in HBV, HCV, and/or HDV infected individuals are not caused by the chronic hepatitis infections per se, but rather are a consequence of underlying CMV infection.

Entities:  

Keywords:  cytomegalovirus; hepatitis B virus; hepatitis C virus; hepatitis delta virus; killer-cell immunoglobulin-like receptor; natural killer cells

Year:  2017        PMID: 28533779      PMCID: PMC5421146          DOI: 10.3389/fimmu.2017.00525

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


Introduction

Infection with cytomegalovirus (CMV) is associated with expansion of a subset of NKG2C-expressing natural killer (NK) cells (1). Such expansions have also been observed in CMV seropositive individuals infected with other infections such as hantavirus (2), HIV-1 (3, 4), and EBV (5). Expanded NK cell populations expressing the activating NKG2C receptor, or CD2 in the case of homozygous deletion of the NKG2C gene (6), are often dominated by the expression of a single inhibitory killer-cell immunoglobulin-like receptor (KIR) receptor (7). NK cell populations with these phenotypic traits have memory-like features including the lack of adaptor proteins EAT-2 (8) and FcεR1γ (9, 10) and have distinct epigenetic characteristics compared to non-expanded NK cells (8, 10, 11). Cytomegalovirus-driven NK cell-expansions have been reported in viral hepatitis infections (12). Furthermore, increased NKG2C-expressing NK cell populations have been observed in patients with chronic hepatitis B virus (HBV) infection (13) or hepatitis C virus (HCV) infection (14). NK cell expansions in CMV seropositive HCV-infected patients share phenotypic traits with expansions found in healthy controls including loss of the FcεR1γ adaptor (15) and superior capacity to respond to CD16 stimulation (12, 15). However, the extents to which different hepatitis virus infections contribute to or modify these NK cell expansions are unknown. To study this, we examined NK cell expansions in HBV-, HCV-, and hepatitis delta virus (HDV)-infected patients in the context of underlying CMV infection by studying the expression of differentiation markers and inhibitory KIRs on NK cells. The results suggest that the presence of adaptive-like NK cell expansions seen in HBV, HCV, and HDV infections is primarily caused by the underlying CMV infection, and not significantly influenced by the hepatitis virus infections per se.

Materials and Methods

Patient Material

Peripheral blood mononuclear cells (PBMCs) from patients used in this study were collected at the outpatient clinic of the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School in Germany. A total of 24 HBV, 18 HCV, and 28 HDV patients were analyzed, of which 20, 12, and 24 were CMV seropositive, respectively. The detailed clinical characteristics of these patients have been reported previously (16). PBMCs from 29 healthy donors, of whom 23 were CMV seropositive, were collected at the Karolinska University Hospital, Stockholm, Sweden. PBMCs were isolated through standard density-gradient separation and cryopreserved for deferred analysis.

Monoclonal Antibodies and Viability Stains

The following monoclonal antibodies were used in the study: CD14-Horizon-V500, CD19-Horizon-V500 (BD Biosciences), CD3-PE-Cy5, CD56-ECD, CD57-PacificBlue, NKG2A-APC (Beckman Coulter), CD4-PE-Cy5, KIR3DL1-Alexa700 (Biolegend), KIR2DL1-biotin, KIR2DL3-FITC, NKG2C-PE (RnD systems), Aqua Dead Cell Stain Kit 405 nm, Strepavidin-Qdot-605, and Qdot-700 (Thermofisher).

Flow Cytometry

Flow cytometry staining was performed as previously described (17). In brief, cryopreserved PBMCs were thawed and washed twice prior to 30 min incubation in the dark at room temperature with the desired antibody combination. Subsequently, the PBMCs were washed once and incubated for 20 min in the dark at room temperature with streptavidin-conjugates. Cells were subsequently washed twice and fixed in 2% PFA for 10 min in the dark at 4°C. Data were acquired on a BD LSRFortessa and analyzed with FlowJo software version 9.8 (LLC, OR, USA).

CMV Serology

Cytomegalovirus IgG serology on hepatitis samples was determined at Hannover Medical School, Hannover; serology on the healthy control samples was determined at Karolinska Institutet, Sweden; both centers used Abbott ARCHITECT Anti-Cytomegalovirus IgG tests.

Statistical Methods, Analysis Strategies, and Outlier Identification

Since expanded NK cell subsets have narrow KIR-repertoires often dominated by a single inhibitory receptor, different statistical strategies aimed at identifying outliers have previously been utilized to identify NK cell expansions (7, 18, 19). For cohorts significantly larger than ours, the Chauvenet criterion has been applied to select for NK cell expansions combined with cellular maturation (7, 18). However, along with our smaller cohorts, the lower expression of some KIRs during hepatitis infections may affect selection. In line with how we previously identified NK cell expansions (19), a variation of the Tukey’s range test accounting for the cohort size was utilized to identify potential NK cell expansions. In more detail, CD56dim NK cells were subdivided into subsets based upon their expression of NKG2A and NKG2C. Subsequently, the expression repertoire of KIR2DL1, KIR2DL3, and KIR3DL1 was assessed. Particular KIR-defined subpopulations were considered as expanded populations if their population frequency was greater than one interquartile range above quartile three in each cohort. Threshold population sizes of either 5 or 20% were both analyzed. Further ensuring that the particular KIR-expressing NK cell subpopulation was a substantial constituent of the NK cell subset (e.g., NKG2ANKG2C+), it was required to be greater than quartile one of the NK cell subset. Finally the geometric MFI of CD57 on the KIR-expressing NK cell subpopulation had to be greater than the geometric MFI of the subject’s total CD56dim NK cells, ensuring that the identified outliers contained terminally differentiated NK cells (7, 20). Identifications of NK cell expansions were performed using Microsoft Excel version 14.4.3 (Microsoft Corporation, Washington, USA). Data were analyzed using Prism version 5.0d (GraphPad Software Inc., CA, USA). For the discrete statistics, non-parametric tests were used as outlined in the respective figure legends.

Results

Validation of CMV-Associated Alterations in NK Cell Differentiation Status

First, NK cell differentiation-associated receptors NKG2A, CD57, and NKG2C, as well as inhibitory receptors KIR2DL1, KIR2DL3, and KIR3DL1 were stained for on CD56dim NK cells (Figure 1A). Expression of these markers was assessed in relation to CMV serostatus in the entire study cohort. As expected from previous reports (1, 21), CMV infection was associated with a higher frequency of CD56dim NK cells expressing NKG2C and CD57, and with lower NKG2A expression compared to CMV seronegative individuals. However, CMV serostatus did not significantly alter expression of individual KIRs (Figure 1B).
Figure 1

Role of underlying cytomegalovirus (CMV) infection in chronic viral hepatitis infections with respect to effects of natural killer (NK) cell differentiation and killer-cell immunoglobulin-like receptor (KIR) expression. (A) Representative staining of differentiation-associated receptors on CD56dim NK cells. Data shown from total lymphocytes have CD3, CD4, CD14, CD19, and dead cell marker positive cells excluded. (B) Expression of NKG2A, CD57, NKG2C, KIR2DL1, KIR2DL3, and KIR3DL1 on CD56dim NK cells in CMV seronegative (CMV−) or seropositive (CMV+) individuals, irrespective of hepatitis status; CMV− n = 9 and CMV+ n = 79. Statistical analysis performed with Mann–Whitney test. (C) Expression of NKG2A, CD57, NKG2C, KIR2DL1, KIR2DL3, and KIR3DL1 on CD56dim NK cells in CMV seropositive individuals split into healthy (n = 23) and hepatitis virus infected [n = 20, 12, and 24 for hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis delta virus (HDV), respectively]. Statistical analysis performed with Kruskal–Wallis test and Dunn’s multiple comparison. Gray bar indicates median. *p < 0.05.

Role of underlying cytomegalovirus (CMV) infection in chronic viral hepatitis infections with respect to effects of natural killer (NK) cell differentiation and killer-cell immunoglobulin-like receptor (KIR) expression. (A) Representative staining of differentiation-associated receptors on CD56dim NK cells. Data shown from total lymphocytes have CD3, CD4, CD14, CD19, and dead cell marker positive cells excluded. (B) Expression of NKG2A, CD57, NKG2C, KIR2DL1, KIR2DL3, and KIR3DL1 on CD56dim NK cells in CMV seronegative (CMV−) or seropositive (CMV+) individuals, irrespective of hepatitis status; CMV− n = 9 and CMV+ n = 79. Statistical analysis performed with Mann–Whitney test. (C) Expression of NKG2A, CD57, NKG2C, KIR2DL1, KIR2DL3, and KIR3DL1 on CD56dim NK cells in CMV seropositive individuals split into healthy (n = 23) and hepatitis virus infected [n = 20, 12, and 24 for hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis delta virus (HDV), respectively]. Statistical analysis performed with Kruskal–Wallis test and Dunn’s multiple comparison. Gray bar indicates median. *p < 0.05.

Viral Hepatitis Does Not Alter NK Cell Differentiation as Assessed in CMV Seropositive Patients and Controls

Of the 88 individuals assessed in the entire study cohort, 79 were confirmed CMV seropositive permitting us to study the influence of hepatitis infection on a CMV seropositive background in relation to NK cell differentiation (Figure 1C). No major differences in expression of NKG2A, NKG2C, or CD57 were observed when comparing CD56dim NK cells in CMV seropositive chronic hepatitis patients with corresponding CMV seropositive healthy controls (Figure 1C). A recently published study including the same patient cohorts indicated that there was no overall difference in the expression of inhibitory KIRs on NK cells during hepatitis infection compared to healthy controls (16). However, in that report expression patterns of individual KIRs were not assessed. Here, a more detailed examination was performed. NK cells from CMV seropositive HCV-infected patients showed a significant decrease in expression of KIR2DL1 and KIR3DL1 relative to healthy controls, while expression of KIR2DL3 was unaltered (Figure 1C). HBV infection and HDV infection had no significant impact on KIR expression (Figure 1C).

Presence of CMV-Driven NK Cell Expansions Remain Unaltered in Chronic Viral Hepatitis

As described, expansions of NKG2C+ NK cells with a specific KIR-repertoire driven by CMV infection have been observed in chronic hepatitis virus infections (12). However, whether hepatitis virus infection affects the prevalence of these expansions is unknown. Adaptive-like NK cell expansions have previously been identified based on deviations in KIR expression profiles, using statistical strategies such as the Chauvenet criterion (7, 18) and the Tukey’s range test (19), combined with cellular differentiation. As our analysis included patients with different hepatitis infections, likely affecting receptor expression to varying degrees, each group was analyzed separately. NK cell subsets were assessed for the presence of expansions (see Materials and Methods) and quantified (Figures 2A–C). For both NKG2ANKG2C− and NKG2ANKG2C+ NK cell subsets, there was no overall difference in the number of CMV seropositive individuals with NK cell expansions, irrespective of chronic hepatitis virus infections (Figure 2D). Since only 9 out of 88 studied patients were CMV seronegative, it was not possible to determine the influence of chronic viral hepatitis on potential expansions within this cohort. Together, we conclude that there is no difference between the prevalence of adaptive-like NK cell expansions observed in CMV seropositive subjects with HBV, HCV, and HDV infection as compared to CMV seropositive healthy controls.
Figure 2

Chronic viral hepatitis does not affect the frequency of cytomegalovirus (CMV)-driven natural killer (NK) cell expansions. (A–C) Killer-cell immunoglobulin-like receptor (KIR)-repertoire and adaptive-like NK cell expansions within NKG2A+NKG2C+/− (A), NKG2A−NKG2C− (B), and NKG2A−NKG2C+ (C) CD56dim NK cell populations in CMV seropositive individuals. Upper-row figures display all KIR subpopulations [n = 23, 20, 12, and 24 for healthy individuals and hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis delta virus (HDV) infected individuals, respectively]. Gray bar indicates median. Bottom-row figures display the identified expansions. The dark gray shading indicates a 5% and the light gray shading a 20% threshold for confirmation of expansions. (D) Percentage of CMV seropositive individuals that have at least one measured expansion within the CD56dim NK cell population. Twenty percent threshold results depicted in light colored bars. Chi-squared test for all NK cell subsets: healthy, p < 0.02; HBV, p < 0.04; HCV, p < 0.08; HDV, p < 0.01; and between NKG2A− subsets: healthy, p = 1; HBV, p = 0.27; HCV, p = 1; HDV, p < 0.17. Five percent threshold results depicted as light and dark bars, Chi-squared test for all NK subsets: healthy, p < 0.03; HBV, p < 0.074; HCV, p < 0.03; HDV, p = 0.0004; and between NKG2A− subsets: healthy, p < 0.55; HBV, p < 0.3; HCV, p = 1; HDV, p < 0.06.

Chronic viral hepatitis does not affect the frequency of cytomegalovirus (CMV)-driven natural killer (NK) cell expansions. (A–C) Killer-cell immunoglobulin-like receptor (KIR)-repertoire and adaptive-like NK cell expansions within NKG2A+NKG2C+/− (A), NKG2ANKG2C− (B), and NKG2ANKG2C+ (C) CD56dim NK cell populations in CMV seropositive individuals. Upper-row figures display all KIR subpopulations [n = 23, 20, 12, and 24 for healthy individuals and hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis delta virus (HDV) infected individuals, respectively]. Gray bar indicates median. Bottom-row figures display the identified expansions. The dark gray shading indicates a 5% and the light gray shading a 20% threshold for confirmation of expansions. (D) Percentage of CMV seropositive individuals that have at least one measured expansion within the CD56dim NK cell population. Twenty percent threshold results depicted in light colored bars. Chi-squared test for all NK cell subsets: healthy, p < 0.02; HBV, p < 0.04; HCV, p < 0.08; HDV, p < 0.01; and between NKG2A− subsets: healthy, p = 1; HBV, p = 0.27; HCV, p = 1; HDV, p < 0.17. Five percent threshold results depicted as light and dark bars, Chi-squared test for all NK subsets: healthy, p < 0.03; HBV, p < 0.074; HCV, p < 0.03; HDV, p = 0.0004; and between NKG2A− subsets: healthy, p < 0.55; HBV, p < 0.3; HCV, p = 1; HDV, p < 0.06.

Discussion

Adaptive-like expansions of certain NK cell subsets are known to occur in response to human CMV infection. As described, such expansions are typically made up of NKG2C+ NK cells with specific KIR expression patterns. Such expansions have been observed in several viral infections including viral hepatitis infections (12, 15). Yet, it is not known if viral hepatitis infection as such contributes to or promotes the appearance of such expansions, or if effects are primarily due to underlying CMV infection. Utilizing a CMV seropositive patient cohort with different forms of chronic viral hepatitis (HBV, HCV, and HDV), we confirmed the existence of large populations of adaptive-like CD57 expressing NK cells. However, the presence of these expansions was largely unrelated to hepatitis status. Since the vast majority of studied subjects were CMV seropositive, it was not possible to determine the influence of chronic viral hepatitis infections on potential adaptive-like NK cell expansions in CMV seronegative individuals. Based on results obtained in this study, we conclude that the observed expansions in hepatitis virus infected individuals (12) are attributed largely, if not exclusively, to underlying CMV infection. Except for expression of NKG2C combined with a narrow KIR-repertoire, adaptive-like NK cell expansions have also been reported to express high levels of CD57, LILRB1, and CD2 while largely lacking NKG2A, NKp30, CD161, EAT-2, and FcεR1γ expression (2, 6–8). Although the adaptive NK cells display unique functional characteristics (2, 6–8), the phenotypic diversity within adaptive-like expanded subsets appears lower as compared to, e.g., the conventional CD56dim NK cell subset (22, 23). It is currently unclear to which the degree the phenotype of adaptive-like NK cell expansions is affected in settings of disease, e.g., during chronic viral infections. In this study, we utilized expression of NKG2C, KIRs, and CD57 combined with absence of NKG2A to identify adaptive-like NK cell expansions. We could not detect any differences in expression of NKG2A, CD57, and NKG2C when comparing patients with controls. However, it is still plausible that other phenotypic traits associated with adaptive-like expansions are uniquely affected during chronic viral hepatitis. It has been previously shown that KIR2DL2/3 is the most frequently expressed KIR on expanded adaptive-like NK cells during chronic hepatitis virus infections (12). While, we were unable to KIR genotype the present patient cohort, to allow us to precisely examine KIR2DL2 expression, we did observe maintenance of KIR2DL3 expression and down-regulation of KIR2DL1 and KIR3DL1 in chronic hepatitis C compared to healthy controls (Figure 1C). This is in line with previous results from other groups (13, 24). Preservation of expression of KIR2DL3 may be due either to immune adaptation or selective pressure in response to hepatitis infection. Intriguingly, it was recently shown that HCV sequence variation in core protein-derived HLA-presented epitopes alters the binding of KIR2DL3 to its HLA-ligand with functional consequences for NK cells suggesting a potential pathway for viral escape via KIR2DL3 (25). There are contradictory results regarding NKG2C expression on NK cells during hepatitis infections. A systematic review suggested increased levels of NKG2C on CD56dim NK cells during HBV infections relative to healthy donors (26). Further, levels of NKG2C in HBV infections were shown to be greater than those in HCV infections (13), while others have seen increased NKG2C during HCV infection (24). Data from our cohorts do not confirm these reports. As CMV serostatus associates with NKG2C expression, it is possible that these reported discrepancies would disappear had CMV serological status been considered. Indeed, such bias inferred by CMV was previously reported for individuals infected with HIV-1 (4). In this study, we employed a non-parametric method to identify expanded NK cell populations. In brief, CD56dim NK cells were separated into subsets based on expression of NKG2A and NKG2C, further subdivided based upon their expression profile of KIR2DL1, KIR2DL3, and KIR3DL1, and assessed for KIR-expressing NK cell expansions. NK cell expansions were in all assessed patient groups and healthy controls primarily confined within the NKG2ANKG2C+ or the NKG2ANKG2C− groups of CD56dim NK cells (Figures 2A–C). Few, if any, expansions had an NKG2A+ phenotype (Figure 2A). Although NK cell expansions have predominantly been described as NKG2C+ (18), NKG2CCD2+ NK cell expansions have also been reported (6). Therefore, we speculate that the NKG2ANKG2C− NK cell expansions we observed may have had another activating receptor associated with their function, e.g., CD2 or activating KIRs. Taken together, the results validated our statistical strategy for identification of expansions, permitting us to compare how common expanded NK cell subsets were in CMV seropositive individuals with chronic viral hepatitis infections compared to healthy controls. The NK cell expansions that we identified may be the reported adaptive-like NK cells, which lack the adaptor protein FcεR1γ and have been associated with reduced liver damage in HCV infection (15). Thus, the role for such cells, with increased levels of IFN-γ production in response to CD16 stimulation (10), should be thoroughly assessed in acquisition and progression of hepatitis virus infections in future studies. Taken together, these results suggest that the NK cell differentiation status and the presence of NK cells with an adaptive phenotype, when controlled for CMV, remain unaffected by chronic viral hepatitis infection.

Ethics Statement

This study was carried out in accordance with the recommendations of the Ethics Committee of Hannover Medical School, Hannover, Germany with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Ethics Committee of Hannover Medical School, Hannover, Germany.

Author Contributions

DM performed most of the experiments, contributed to study design, acquisition of data, analysis, and drafting of the manuscript; SL performed most of the experiments, contributed to study design, and acquisition of data; JH contributed to study design and analysis; MM, JS, and MC contributed to study design and data interpretation; H-GL and HW contributed to study design, data interpretation, drafting the manuscript, and supervision of the work; NB contributed to study design, data analysis, drafting of the manuscript, and supervised the work.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  26 in total

1.  Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection.

Authors:  Sandra Lopez-Vergès; Jeffrey M Milush; Brian S Schwartz; Marcelo J Pando; Jessica Jarjoura; Vanessa A York; Jeffrey P Houchins; Steve Miller; Sang-Mo Kang; Phillip J Norris; Douglas F Nixon; Lewis L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

Review 2.  Emerging insights into natural killer cells in human peripheral tissues.

Authors:  Niklas K Björkström; Hans-Gustaf Ljunggren; Jakob Michaëlsson
Journal:  Nat Rev Immunol       Date:  2016-04-28       Impact factor: 53.106

3.  Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function.

Authors:  Heinrich Schlums; Frank Cichocki; Bianca Tesi; Jakob Theorell; Vivien Beziat; Tim D Holmes; Hongya Han; Samuel C C Chiang; Bree Foley; Kristin Mattsson; Stella Larsson; Marie Schaffer; Karl-Johan Malmberg; Hans-Gustaf Ljunggren; Jeffrey S Miller; Yenan T Bryceson
Journal:  Immunity       Date:  2015-03-17       Impact factor: 31.745

4.  Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients.

Authors:  Monica Gumá; Cecilia Cabrera; Itziar Erkizia; Margarita Bofill; Bonaventura Clotet; Lidia Ruiz; Miguel López-Botet
Journal:  J Infect Dis       Date:  2006-05-24       Impact factor: 5.226

5.  Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education.

Authors:  Niklas K Björkström; Peggy Riese; Frank Heuts; Sandra Andersson; Cyril Fauriat; Martin A Ivarsson; Andreas T Björklund; Malin Flodström-Tullberg; Jakob Michaëlsson; Martin E Rottenberg; Carlos A Guzmán; Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  Blood       Date:  2010-08-09       Impact factor: 22.113

6.  Cutting edge: NKG2C(hi)CD57+ NK cells respond specifically to acute infection with cytomegalovirus and not Epstein-Barr virus.

Authors:  Deborah W Hendricks; Henry H Balfour; Samantha K Dunmire; David O Schmeling; Kristin A Hogquist; Lewis L Lanier
Journal:  J Immunol       Date:  2014-04-16       Impact factor: 5.422

7.  Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections.

Authors:  Barbara Oliviero; Stefania Varchetta; Enrica Paudice; Giuseppe Michelone; Marco Zaramella; Domenico Mavilio; Francesca De Filippi; Savino Bruno; Mario U Mondelli
Journal:  Gastroenterology       Date:  2009-05-24       Impact factor: 22.682

8.  Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.

Authors:  Golo Ahlenstiel; Rachel H Titerence; Christopher Koh; Birgit Edlich; Jordan J Feld; Yaron Rotman; Marc G Ghany; Jay H Hoofnagle; T Jake Liang; Theo Heller; Barbara Rehermann
Journal:  Gastroenterology       Date:  2009-09-10       Impact factor: 22.682

9.  Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells.

Authors:  Merlin Luetke-Eversloh; Quirin Hammer; Pawel Durek; Karl Nordström; Gilles Gasparoni; Matthias Pink; Alf Hamann; Jörn Walter; Hyun-Dong Chang; Jun Dong; Chiara Romagnani
Journal:  PLoS Pathog       Date:  2014-10-16       Impact factor: 6.823

10.  Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient Humans.

Authors:  Lisa L Liu; Johannes Landskron; Eivind H Ask; Monika Enqvist; Ebba Sohlberg; James A Traherne; Quirin Hammer; Jodie P Goodridge; Stella Larsson; Jyothi Jayaraman; Vincent Y S Oei; Marie Schaffer; Kjetil Taskén; Hans-Gustaf Ljunggren; Chiara Romagnani; John Trowsdale; Karl-Johan Malmberg; Vivien Béziat
Journal:  Cell Rep       Date:  2016-04-21       Impact factor: 9.423

View more
  14 in total

1.  HCMV jogs the 'memory' of NK cells in HBV.

Authors:  Upkar S Gill; Lucy Golden-Mason
Journal:  J Hepatol       Date:  2018-12-11       Impact factor: 30.083

2.  Influence of HLA-C environment on the spontaneous clearance of hepatitis C in European HIV-HCV co-infected individuals.

Authors:  N Legrand; G David; C Retière; C Allavena; A Rodallec; A Gaultier; D Salmon; A Cesbron; L Wittkop; F Raffi; K Gendzekhadze; K Gagne
Journal:  Clin Exp Immunol       Date:  2021-02-02       Impact factor: 5.732

Review 3.  Natural Killer Cells in Human Immunodeficiency Virus-1 Infection: Spotlight on the Impact of Human Cytomegalovirus.

Authors:  Dimitra Peppa
Journal:  Front Immunol       Date:  2017-10-17       Impact factor: 7.561

4.  The Clinical Features of Patients with Chronic Hepatitis C Virus Infections Are Associated with Killer Cell Immunoglobulin-Like Receptor Genes and Their Expression on the Surface of Natural Killer Cells.

Authors:  Ariel Podhorzer; Melisa Dirchwolf; Andrés Machicote; Santiago Belen; Silvina Montal; Silvia Paz; Hugo Fainboim; Luis G Podestá; Leonardo Fainboim
Journal:  Front Immunol       Date:  2018-01-05       Impact factor: 7.561

5.  Cytomegalovirus-Driven Adaption of Natural Killer Cells in NKG2Cnull Human Immunodeficiency Virus-Infected Individuals.

Authors:  Emilie M Comeau; Kayla A Holder; Neva J Fudge; Michael D Grant
Journal:  Viruses       Date:  2019-03-09       Impact factor: 5.048

Review 6.  The Good and the Bad of Natural Killer Cells in Virus Control: Perspective for Anti-HBV Therapy.

Authors:  Paola Fisicaro; Marzia Rossi; Andrea Vecchi; Greta Acerbi; Valeria Barili; Diletta Laccabue; Ilaria Montali; Alessandra Zecca; Amalia Penna; Gabriele Missale; Carlo Ferrari; Carolina Boni
Journal:  Int J Mol Sci       Date:  2019-10-13       Impact factor: 5.923

Review 7.  Natural killer cells in antiviral immunity.

Authors:  Niklas K Björkström; Benedikt Strunz; Hans-Gustaf Ljunggren
Journal:  Nat Rev Immunol       Date:  2021-06-11       Impact factor: 53.106

8.  Adaptive Natural Killer Cells Integrate Interleukin-18 during Target-Cell Encounter.

Authors:  Quirin Hammer; Timo Rückert; Josefine Dunst; Chiara Romagnani
Journal:  Front Immunol       Date:  2018-01-17       Impact factor: 7.561

Review 9.  Innate immune responses in RNA viral infection.

Authors:  Qian Xu; Yuting Tang; Gang Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 9.927

Review 10.  Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.

Authors:  Stephan Urban; Christoph Neumann-Haefelin; Pietro Lampertico
Journal:  Gut       Date:  2021-06-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.